Today, AMP started an initial position in Adamas Pharmaceuticals (ADMS) with a starting position of $12,500. ADMS has a target PDUFA date for it's ADS-5102 program in Parkinson's patients with levodopa induced dyskinesia (LID) of August 24 and AMP is cautiously optimistic of drug's chances of approval.
You can read more about ADMS in our recently published post here.